Omniscan
FDA Wants Consumers to Report Problems »
"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...
Omniscan
OVERDOSE
Clinical consequences of overdose with OMNISCAN (gadodiamide) have not been reported. The minimum lethal dose of intravenously administered OMNISCAN (gadodiamide) in rats and mice is greater than 20 mmol/kg (200 times the recommended human dose of 0.1 mmol/kg; 67 times the cumulative 0.3 mmol/kg dose). OMNISCAN (gadodiamide) is dialyzable.
CONTRAINDICATIONS
OMNISCAN (gadodiamide) is contraindicated in patients with:
- chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min/1.73m²), or
- acute kidney injury.
Last reviewed on RxList: 2/11/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Omniscan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
